Provenge in 2008 hinges on interim data
Executive Summary
FDA will accept interim data from ongoing IMPACT study as a basis for resubmission of Dendreon's prostate cancer vaccine Provenge (sipuleucel-T). Data from the Phase III study are expected in mid-to-late 2008, CEO Mitchell Gold says during the Bank of America Health Care conference May 31. If the interim analysis does not show improved patient survival, the review would be further delayed until at least 2010, when final data are anticipated. FDA issued a "complete response" letter seeking additional efficacy data on the prostate cancer treatment May 8 (1"The Pink Sheet" May 14, 2007, In Brief)...
You may also be interested in...
Provenge set back until 2008
Approval of Dendreon's therapeutic cancer vaccine Provenge (sipuleucel-T) could be based on an interim analysis of an ongoing Phase III study called IMPACT, expected in 2008, CEO Mitchell Gold says during a first quarter conference call May 11. The firm believes it has the necessary cash balance to fund the company through the interim analysis, but would likely seek refinancing prior to resubmitting Provenge to FDA. The update comes after Dendreon was dealt a blow by FDA when the agency issued a "complete response" letter seeking additional efficacy data on the prostate cancer treatment May 8. FDA's action departs from the recommendation by the agency's Cellular, Tissue and Gene Therapies Advisory Committee, which had issued a favorable recommendation on efficacy (1"The Pink Sheet" April 9, 2007, p. 7)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.